KUALA LUMPUR, Jan 30 — The sale of anti-retroviral therapy drugs (Highly Active Antiretroviral Therapy — HAART) that is trending on social media site X is included in the category of controlled substances regulated under the Poisons Act 1952.

PUTRAJAYA, Dec 11 — Medical gas products must be licenced and registered from January 1, 2023, to ensure products supplied to patients and consumers are of quality as well as safe and effective.

PUTRAJAYA, Oct 24 — The Health Ministry (MOH) has revoked the notification of five cosmetic products found to contain scheduled poisons, which are no longer allowed to be sold in Malaysia.

KUALA LUMPUR, Oct 7 — The Ministry of Health (MOH) has approved the registration of Xenpozyme (olipudase alfa 20mg) to treat patients suffering from Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease.

PUTRAJAYA, July 10 — The product notification for Airee Beautycare Night Cream and BL Ledehh Day Cream 1 has been revoked as they were found to contain scheduled poisons, and are no longer allowed to be sold in Malaysia.

KUALA LUMPUR, May 1 — A cough syrup product, Guaifenesin Syrup TG Syrup, manufactured by QP Pharmachem Ltd.

PUTRAJAYA, April 6 — The Ministry of Health (MOH) has agreed to give 'orphan medicine’ status to Koselugo Hard Capsules 10mg and 25mg, said Health Director-General Tan Sri Dr Noor Hisham Abdullah.

KUALA LUMPUR, March 23 — The Ministry of Health (MOH) has issued a cancellation and recall on all registered products containing pholcodine.

KUALA LUMPUR, March 22 — The National Pharmaceutical Regulatory Agency (NPRA) under the Health Ministry (MoH) has revoked the notification of six cosmetic products because they were found to contain scheduled poisons.

PUTRAJAYA, Feb 13 — The sale of two cosmetic products of the brand name Karisma, namely its Turmeric Booster Cream and Flashhskinzz Treatment Cream, are no longer allowed in Malaysia as they are found to contain mercury, which is a scheduled poison, said Health director-general Tan Sri Dr Noor Hisham Abdullah.

PUTRAJAYA, Feb 8 — The company that has been granted conditional registration approval for Lagevrio for the treatment of Covid-19 must submit the latest safety data from time to time through rolling submission to the National Pharmaceutical Regulatory Agency (NPRA), said its director Rosilawati Ahmad.

PUTRAJAYA, Jan 20 — The National Pharmaceutical Regulatory Agency (NPRA) has approved a variation application from Pfizer (Malaysia) Sdn Bhd in relation to updating the shelf life of Covid-19 Comirnaty Concentrate for Dispersion for Injection vaccine.

KUALA LUMPUR, Jan 18 — No cases of stroke were reported for the Comirnaty Bivalent COVID-19 vaccine in the clinical studies conducted, according to the data submitted by the product registration holder, Pfizer Sdn Bhd to the National Pharmaceutical Regulatory Agency (NPRA).

PUTRAJAYA, Jan 13 — The National Pharmaceutical Regulatory Agency (NPRA) has approved a variation application for the extension of the shelf life of seven Covid-19 vaccine products from April 28 to December 20 last year.

PUTRAJAYA, Jan 10 — The shelf life of the Covid-19 vaccines used in Malaysia has been extended after the manufacturing company submitted new data on the stability of the vaccine, said Health director-general Tan Sri Dr Noor Hisham Abdullah.

KUALA LUMPUR, Oct 24 — Five syrup medicines linked to the deaths of children in Indonesia are not registered in Malaysia, Health Ministry (MoH) senior director of pharmacy services Norhaliza A Halim said.

KUALA LUMPUR, Oct 23 — The National Pharmaceutical Regulatory Agency (NPRA), under the Ministry of Health (MOH), has cancelled the notification of five cosmetic products found to contain scheduled poisons.

PUTRAJAYA, March 2 — Twenty-two out of 45 deaths involving recipients of the Covid-19 booster dose that were reported to the National Pharmaceutical Regulatory Agency (NPRA) were found to be unrelated to the vaccine.

KUALA LUMPUR, Feb 10 — The Covaxin Covid-19 vaccine has been given conditional approval for use during disasters, Health director-general Tan Sri Dr Noor Hisham Abdullah said.

PUTRAJAYA, Feb 9 — The National Pharmaceutical Regulatory Agency (NPRA) has received 1,047 reports of adverse events following immunisation (AEFI) associated with the Covid-19 Pfizer-BioNTech vaccine as of January 31, said its director Dr Roshayati Mohamad Sani.